In 2021, the FDA’s Purple Book went live, providing a searchable database of licensed biological products, including the patent information provided to biosimilar applicants during the patent dance. Pursuant to a law enacted...more
As we close out another calendar year, we look back at the top legal developments of 2021 that could influence the market for biologics and biosimilars. There were many interesting decisions and other developments in district...more
12/28/2021
/ AbbVie ,
Antitrust Litigation ,
Biosimilars ,
Fresenius ,
Generic Drugs ,
International Trade Commission (ITC) ,
Johnson & Johnson ,
Mylan Pharmaceuticals ,
Orange Book ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Prescription Drugs ,
Proposed Legislation ,
Sanofi ,
Sherman Act ,
The Clayton Act